5-methylbenzo[2,1,3]thiadiazole-4-sulfonyl chloride | 3662-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: 5-methylbenzo[2,1,3]thiadiazole-4-sulfonyl chloride
• 英文别名: 5-Methyl-2,1,3-benzothiadiazole-4-sulfonyl chloride
• CAS: 3662-82-6
• 化学式: C₇H₅ClN₂O₂S₂
• mdl: MFCD02232191
• 分子量: 248.714
• InChiKey: TWWDPSJSTXBULL-UHFFFAOYSA-N

物化性质

• 熔点：
  152-153 °C
• 沸点：
  373.0±30.0 °C(Predicted)
• 密度：
  1.631±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  96.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-methylbenzo[2,1,3]thiadiazole-4-sulfonyl chloride 在 氢碘酸 作用下， 以 溶剂黄146 为溶剂， 反应 12.0h， 以77%的产率得到5-Methyl-4-[(5-methyl-2,1,3-benzothiadiazol-4-yl)disulfanyl]-2,1,3-benzothiadiazole
  参考文献：
  名称：

  Disulfides of the benzo-2,1,3-thiadiazole series

  摘要：

  DOI：

  10.1007/bf00481530

文献信息

• Identification and Optimization of Anthranilic Sulfonamides as Novel, Selective Cholecystokinin-2 Receptor Antagonists
  作者：Brett D. Allison、Victor K. Phuong、Laura C. McAtee、Mark Rosen、Magda Morton、Clodagh Prendergast、Terry Barrett、Guy Lagaud、Jamie Freedman、Lina Li、Xiaodong Wu、Hariharan Venkatesan、Marna Pippel、Craig Woods、Michèle C. Rizzolio、Michael Hack、Kenway Hoey、Xiaohu Deng、Christopher King、Nigel P. Shankley、Michael H. Rabinowitz

  DOI：10.1021/jm060590x

  日期：2006.10.1

  A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-5-chlorobenzoyl]-piperidine (1; CCK-2R, pK(I) = 6.4). Preliminary exploration of the structure-activity relationships around the anthranilic ring and the amide and

  一种高通量筛选方法，用于鉴定选择性胆囊收缩素2受体（CCK-2R）配体，从而发现了一系列新型的拮抗剂，以1- [2-[（2,1,3-benzothiadiazol-4- （磺酰基）氨基] -5-氯苯甲酰基]-哌啶（1； CCK-2R，pK（I）＝ 6.4）。对邻氨基苯甲酸环以及酰胺和磺酰胺基团周围的结构活性关系的初步探索导致受体亲和力提高了近50倍，并且相对于相关的胆囊收缩素1受体显示出超过1000倍的选择性。药代动力学评估导致鉴定了4- [4-碘-2-[（5-喹喔啉基磺酰基）氨基]苯甲酰基]-吗啉，26d，
• [EN] 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10<br/>[FR] ANTAGONISTES DE 2-SULFONYLAMINO-4-HÉTÉROARYL BUTYRAMIDE DE CCR10
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009126675A1

  公开（公告）日：2009-10-15

  This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.

  本发明涉及一种具有式（I）的化合物及其药学上可接受的盐，其中R1、R2、R4、Ar和Het如本文中所定义。该发明还涉及使用式（I）的化合物治疗通过CCR10活性介导或维持的疾病和紊乱的方法。
• 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10
  申请人：Abeywardane Asitha

  公开号：US20110275800A1

  公开（公告）日：2011-11-10

  This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 4 . Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR 10 .

  本发明涉及公式(I)的化合物及其药学上可接受的盐，其中R1、R2、R4、Ar和Het的定义如本文所述。本发明还涉及使用公式(I)的化合物治疗通过CCR10活性介导或持续的疾病和障碍的方法。
• Disulfides of the benzo-2,1,3-thiadiazole series
  作者：I. A. Belen'kaya、T. A. Shulla

  DOI：10.1007/bf00481530

  日期：1989.11
• Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012
  作者：Bruce J. Melancon、Alexander P. Lamers、Thomas M. Bridges、Gary A. Sulikowski、Thomas J. Utley、Douglas J. Sheffler、Meredith J. Noetzel、Ryan D. Morrison、J. Scott Daniels、Colleen M. Niswender、Carrie K. Jones、P. Jeffrey Conn、Craig W. Lindsley、Michael R. Wood

  DOI：10.1016/j.bmcl.2011.11.110

  日期：2012.1

  This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M-1-selective antagonist, compound 13I (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13I, along with rat selectivity for the lead compound (ML012), is presented. (C) 2011 Elsevier Ltd. All rights reserved.